NPM1 and acute myeloid leukemia: AML patients with NPM1 mutations have shown a composite remission of 66.7% in the phase 3 trial of VEN plus azacytidine (AZA), and the CR/CRi/CR with partial hematologic recovery was 78% in the trial with LDAC plus VEN [8,62].